The stock of Myriad Genetics, Inc (NASDAQ: MYGN) has increased by 9.42 when compared to last closing price of 4.46. Despite this, the company has experienced a 17.59% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-03 that Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing
Is It Worth Investing in Myriad Genetics, Inc (NASDAQ: MYGN) Right Now?
The 36-month beta value for MYGN is also noteworthy at 1.85. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 9 rating it as “hold,” and 1 rating it as “sell.”
The public float for MYGN is 87.74M, and at present, short sellers hold a 9.03% of that float. The average trading volume of MYGN on June 04, 2025 was 1.97M shares.
MYGN’s Market Performance
MYGN stock saw a decrease of 17.59% in the past week, with a monthly decline of -35.45% and a quarterly a decrease of -53.17%. The volatility ratio for the week is 5.80%, and the volatility levels for the last 30 days are 13.22% for Myriad Genetics, Inc (MYGN). The simple moving average for the past 20 days is 12.36% for MYGN’s stock, with a -68.04% simple moving average for the past 200 days.
Analysts’ Opinion of MYGN
Many brokerage firms have already submitted their reports for MYGN stocks, with Scotiabank repeating the rating for MYGN by listing it as a “Sector Perform.” The predicted price for MYGN in the upcoming period, according to Scotiabank is $6 based on the research report published on May 21, 2025 of the current year 2025.
Wells Fargo gave a rating of “Equal Weight” to MYGN, setting the target price at $6 in the report published on May 07th of the current year.
MYGN Trading at -26.10% from the 50-Day Moving Average
After a stumble in the market that brought MYGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.34% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MYGN starting from DIAZ PAUL J, who sale 15,000 shares at the price of $22.93 back on Oct 11 ’24. After this action, DIAZ PAUL J now owns 962,378 shares of Myriad Genetics, Inc, valued at $343,950 using the latest closing price.
DIAZ PAUL J, the Officer of Myriad Genetics, Inc, proposed sale 15,000 shares at $22.93 during a trade that took place back on Oct 11 ’24, which means that DIAZ PAUL J is holding shares at $343,950 based on the most recent closing price.
Stock Fundamentals for MYGN
Current profitability levels for the company are sitting at:
- -0.14 for the present operating margin
- 0.69 for the gross margin
The net margin for Myriad Genetics, Inc stands at -0.14. The total capital return value is set at -0.12. Equity return is now at value -13.84, with -9.58 for asset returns.
Based on Myriad Genetics, Inc (MYGN), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -0.49. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -38.6.
Currently, EBITDA for the company is -186.1 million with net debt to EBITDA at -0.87. When we switch over and look at the enterprise to sales, we see a ratio of 0.6. The receivables turnover for the company is 6.55for trailing twelve months and the total asset turnover is 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.90.
Conclusion
In summary, Myriad Genetics, Inc (MYGN) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
